PREDICT v2.0在线预测工具在荷兰乳腺癌人群中的验证
本研究基于荷兰全国癌症登记处2005年确诊的非转移性浸润性乳腺癌手术患者8834例,验证PREDICT v2.0对5年和10年总生存的预测效能。结果显示整体判别能力良好(5年AUC 0.80,10年AUC 0.78),但ER阴性患者预测偏差接近临床相关阈值,≥75岁、T3肿瘤及接受内分泌联合化疗者10年生存预测需谨慎解读。
要点
- PREDICT v2.0在荷兰乳腺癌整体人群中预测5年和10年OS判别能力良好。
- ER阴性患者5年和10年OS预测偏差分别为-4.9%和-5.3%,需谨慎解读。
- ≥75岁、T3肿瘤及内分泌联合化疗者10年OS预测偏差较大,应慎用。
核心结论
- PREDICT v2.0在多数荷兰乳腺癌患者中能可靠预测总生存,但ER阴性患者及特定亚组(≥75岁、T3肿瘤、接受内分泌联合化疗者)的预测结果需谨慎解读。
研究设计与样本
- 基于荷兰全国癌症登记处(NCR)2005年确诊的所有接受手术的非转移性原发性浸润性乳腺癌女性,共纳入8834例患者。
- 比较PREDICT v2.0预测与观察的5年和10年总生存(OS),按ER状态及预设亚组分析,以差异>5%为临床相关。
- 采用受试者工作特征曲线下面积(AUC)和卡方检验评估判别准确性和拟合优度。
主要发现
- 5年OS判别能力良好(整体AUC 0.80),ER阳性和ER阴性患者AUC分别为0.79和0.75。
- 5年OS预测值与观察值差异:整体-1.4%,ER阳性-0.7%,ER阴性-4.9%。
- 10年OS判别能力良好(整体AUC 0.78),ER阳性和ER阴性患者AUC分别为0.78和0.76。
- 10年OS预测值与观察值差异:整体-1.0%,ER阳性-0.1%,ER阴性-5.3%。
关键数值与推荐
- 以预测值与观察值差异>5%作为临床相关性阈值。
- 5年OS在全部预设亚组中预测准确。
- ER阴性患者5年和10年OS预测偏差分别为-4.9%和-5.3%,接近或超过临床相关阈值。
临床怎么用
- PREDICT v2.0可用于荷兰乳腺癌患者总体预后评估,但ER阴性患者的5年和10年OS预测应谨慎解读。
- 对≥75岁、T3肿瘤及考虑内分泌联合化疗的患者,10年OS预测结果需谨慎用于临床决策。
局限性
- 研究仅纳入2005年确诊患者,未反映后续治疗变化对预后的影响。
- 验证人群为荷兰全国登记数据,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PREDICT version 2.0 is increasingly used to estimate prognosis in breast cancer. This study aimed to validate this tool in specific prognostic subgroups in the Netherlands. METHODS: All operated women with non-metastatic primary invasive breast cancer, diagnosed in 2005, were selected from the nationwide Netherlands Cancer Registry (NCR). Predicted and observed 5- and 10-year overall survival (OS) were compared for the overall cohort, separated by oestrogen receptor (ER) status, and predefined subgroups. A >5% difference was considered as clinically relevant. Discriminatory accuracy and goodness-of-fit were determined using the area under the receiver operating characteristic curve (AUC) and the Chi-squared-test. RESULTS: We included 8834 patients. Discriminatory accuracy for 5-year OS was good (AUC 0.80). For ER-positive and ER-negative patients, AUCs were 0.79 and 0.75, respectively. Predicted 5-year OS differed from observed by -1.4% in the entire cohort, -0.7% in ER-positive and -4.9% in ER-negative patients. Five-year OS was accurately predicted in all subgroups. Discriminatory accuracy for 10-year OS was good (AUC 0.78). For ER-positive and ER-negative patients AUCs were 0.78 and 0.76, respectively. Predicted 10-year OS differed from observed by -1.0% in the entire cohort, -0.1% in ER-positive and -5.3 in ER-negative patients. Ten-year OS was overestimated (6.3%) in patients ≥75 years and underestimated (-13.%) in T3 tumours and patients treated with both endocrine therapy and chemotherapy (-6.6%). CONCLUSIONS: PREDICT predicts OS reliably in most Dutch breast cancer patients, although results for both 5-year and 10-year OS should be interpreted carefully in ER-negative patients. Furthermore, 10-year OS should be interpreted cautiously in patients ≥75 years, T3 tumours and in patients considering endocrine therapy and chemotherapy.
引用
- van Maaren MC, van Steenbeek CD, Pharoah PDP, et al. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. Eur J Cancer. 2017. PMID: 29100191. doi:10.1016/j.ejca.2017.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。